Abstract

We aimed to distinguish between the effects of mutations in apoA-I on the requirements for the secondary structure and a specific amino acid sequence for lecithin:cholesterol acyltransferase (LCAT) activation. Several mutants were constructed targeting region 140-150: (i) two mutations affecting alpha-helical structure, deletion of amino acids 140-150 and substitution of Ala(143) for proline; (ii) two mutations not affecting alpha-helical structure, substitution of Val(149) for arginine and substitution of amino acids 63-73 for sequence 140-150; and (iii) a mutation in a similar region away from the target area, deletion of amino acids 63-73. All mutations affecting region 140-150 resulted in a 4-42-fold reduction in LCAT activation. Three mutations, apoA-I(Delta140-150), apoA-I(P143A), and apoA-I(140-150 --> 63-73), affected both the apparent V(max) and K(m), whereas the mutation apoA-I(R149V) affected only the V(max). The mutation apoA-I(Delta63-73) caused only a 5-fold increase in the K(m). All mutants, except apoA-I(P143A) and apoA-I(Delta63-73), were active in phospholipid binding assay. All mutants, except apoA-I(P143A), formed normal discoidal complexes with phospholipid. The mutation apoA-I(Delta63-73) caused a significant reduction in the stability of apoA-I.phospholipid complexes in denaturation experiments. Combined, our results strongly suggest that although the correct conformation and orientation of apoA-I in the complex with lipids are crucial for activation of LCAT, when these conditions are fulfilled, activation also strongly depends on the sequence that includes amino acids 140-150.

Highlights

  • ApoA-I is a key element of the reverse cholesterol transport pathway

  • Our results strongly suggest that the correct conformation and orientation of apoA-I in the complex with lipids are crucial for activation of lecithin:cholesterol acyltransferase (LCAT), when these conditions are fulfilled, activation strongly depends on the sequence that includes amino acids 140 –150

  • The sequence between amino acids 140 and 150 belongs to the central domain of apoA-I that is implicated in the ability of apoA-I to activate LCAT and that may be involved in the stimulation of efflux of intracellular cholesterol [15]

Read more

Summary

Introduction

ApoA-I is a key element of the reverse cholesterol transport pathway. This pathway removes excess cholesterol from extrahepatic cells and protects the artery wall against developing atherosclerosis [1]. ApoA-I regulates the translocation of intracellular cholesterol to the plasma membrane [11, 12], promotes efflux of intracellular cholesterol [13,14,15,16], triggers signaling pathways that could be related to cholesterol efflux [17,18,19], and regulates expression of adhesion molecules [20] Many of these activities are related to the unique secondary structure of apoA-I: when bound to lipid, apoA-I consists of nine 22-mer and two 11-mer amphipathic ␣-helices spanning almost the entire length of apoA-I [21]. We show that in addition to the carboxyl-terminal end sites, a lipid-binding domain of apoA-I might reside between amino acids 63 and 73

Objectives
Methods
Results
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call